GenEdit's delivery vehicle

GenEdit’s proprietary technology can enable the delivery of specific gene editors to a variety of tissues using nanoparticles which are non-viral and polymer-based delivery vehicles.

Nanoparticles_v1.jpg
 

GenEdit's platform enables broad product opportunity

Genetic diseases are found in various organs including brain, muscle, liver, or blood. GenEdit’s technology platform is based on screening its polymer-based nanoparticle library for the best delivery to the target organs. GenEdit’s proprietary nanoparticles can encapsulate gene therapy molecules and CRISPR proteins.

Our recent publications have demonstrated initial proof-of-concept by exhibiting efficient preclinical gene editing in target tissues, specifically the muscle for Duchenne muscular dystrophy (Nature Biomedical Engineering, 2017and the brain for Fragile X syndrome (Nature Biomedical Engineering, 2018). In addition, the polymer library has also enabled the delivery of Cpf1 (Cas12a), a next generation CRISPR, in muscle (Nature Communications, 2018).

Nanoparticle_Screening_v2.jpg